Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Autore:
Hjalmarson, A; Goldstein, S; Fagerberg, B; Wedel, H; Waagstein, F; Kjekshus, J; Wikstrand, J; Hassle, A; Westergren, G; Hassle, A; Thimell, M; El Allaf, D; Vitovec, J; Aldershvile, J; Halinen, M; Dietz, R; Neuhaus, KL; Janosi, A; Thorgeirsson, G; Dunselman, P; Gullestad, L; Kuch, J; Herlitz, J; Rickenbacher, P; Ball, S; Gottlieb, S; Deedwania, P; Vandenhoven, G; Novakova, I; Danker, S; Lundstrom, M; Meyer-Sabellek, W; Balla, I; Sveinsdottir, M; Dorhout, B; Hildebrandt, A; Szczurko, I; Larsson, C; Bucher, E; Scott, E; Dwyer, D; Julian, DG; DeMets, DL; Chatterjee, K; Feyzi, J; Lehto, S; Karpati, P; Motz, W; Samuelsson, O; Viersma, JW; Andersson, B; Berthe, C; Boutefeu, JM; Boxho, G; Decroly, P; Derbaudrenghien, JP; El Allaf, D; Pirlet, J; Henry, P; Heyndrickx, G; Missault, L; Nannan, M; Timmermans, P; Vachiery, JL; Van Mieghem, W; Vandenbossche, JL; Dvorak, K; Herold, M; Hradec, J; Kana, A; Petr, P; Rybka, J; Smid, J; Svitil, P; Toman, J; Vitovec, J; Agner, E; Aldershvile, J; Amtorp, O; Egstrup, K; Eliasen, P; Gotzsche, CO; Hildebrandt, P; Johannesen, A; Kaiser-Nielsen, P; Nielsen, H; Nielsen, PE; Pedersen, F; Nielsen, JR; Skagen, K; Halinen, M; Honkanen, T; Hussi, E; Juvonen, J; Jaaskelainen, H; Rinne, J; Salonen, T; Andresen, D; Berwing, H; Dietz, R; Forster, A; Hauf, GF; Krosse, B; Luderitz, B; von Olshausen, KE; Schmailzl, KJG; Schwimmbeck, PL; Sigmund, M; Voller, H; Czuriga, I; Hetey, M; Janosi, A; Katona, A; Lengyel, M; Nyaradi, A; Rednik, A; Sandori, K; Szabo, P; Tarjan, J; Tenczer, J; Timar, S; Valyi, P; Veress, G; Zamolyi, K; Oze, B; Thorgeirsson, G; Thorgeirsson, G; Bernink, PJLM; Bredero, AC; Breedveld, RW; Breuls, PNWM; Bucx, JJJ; Cornel, JH; De Milliano, PAR; Dunselman, PHJM; Hamer, BJB; Holwerda, NL; Hoogsteen, J; Hoorntje, JCA; Kragten, JA; Liem, AH; Linssen, GCM; Michels, HR; Misier, ARR; Schaafsma, HJ; Sijbring, P; Taverne, RJT; Van Kempen, LHJ; Van Stralen, R; Van Veldhuisen, PJ; Veerhoek, MJ; Werter, CJPJ; Wesdorp, JCL; Willems, AR; Withagen, AJAM; Zwart, PAG; Bjornerheim, R; Dahle, M; Dickstein, K; Froland, GS; Gullestad, L; Gundersen, T; Hofsoy, K; Hole, TL; Johansen, T; Mannsverk, J; Nesje, P; Omland, TM; Sjodin, C; Smith, P; Tjonndal, HA; Vikesdal, O; Waage, K; Jaworska, K; Kolodziej, P; Kornacewicz-Jach, Z; Krzeminska-Pakula, M; Kuch, J; Piotrowski, JW; Piwowarska, W; Stogowski, A; Wodniecki, J; Wrabec, K; Ahlstrom, P; Ekdahl, S; Hemmingson, LO; Herlitz, J; Holmberg, L; Lernfelt, B; Nilsson, H; Widgren, B; Angman, K; Erne, P; Mohacsi, P; Polikar, R; Rickenbacher, P; Schlapfer, H; Batin, P; Berkin, KE; Callaghan, TS; Forfar, J; Frenneaux, M; Greenbaum, RA; Maltz, M; Murdoch, D; Reynolds, G; Stephens, J; Struthers, A; Swan, J; Tildesley, G; Abbasi, A; Alagona, P; Alderman, J; Alipour, M; Anderson, JL; Ansari, Z; Ashraf, M; Beanblossom, BT; Bennett, S; Benvenuti, D; Berk, MR; Bhalla, R; Bilazarian, SD; Browne, KF; Buchter, CM; Carlson, R; Carlson, CJ; Danisa, K; Dauber, I; DeWood, MA; Deedwania, P; Dennish, G; Denny, DM; DiBianco, R; Diller, PM; Dunlap, M; Dowd, K; Edmiston, A; El Shahawy, M; Elkayam, U; Farnham, J; Fenster, P; Friedman, S; Heywood, T; Galichia, JP; Geller, M; Ghali, JK; Gheorghiade, M; Giles, T; Gillespe, R; Goldberg, G; Goldberg, MC; Goldscher, DA; Gooden, GP; Goodman, M; Goodman, L; Gorwit, J; Gottlieb, SS; Gradman, A; Grech, D; Hack, T; Hall, JH; Hattenhauer, MT; Higginbotham, MB; Hutchins, S; Imburgia, M; Iteld, BJ; Jackson, B; Jafri, S; Jauch, W; Jennison, S; Kahn, BH; Kao, W; Kaplan, K; Karlsberg, R; Kennedy, HL; Kennedy, JJ; Kirkegaard, L; Kraus, DH; LaBresh, K; Lalonde, L; Lesser, MF; Levites, R; Levy, M; Lewis, RK; Loh, IK; Madyoon, H; Maislos, F; Mann, D; Maurice, GL; Nisar, A; Old, W; Pappas, JD; Phadke, K; Promisloff, S; Rashkow, AM; Reeves, B; Rosen, JH; Rotman, M; Saleem, T; Savran, SV; Shah, R; Shalev, Y; Shanes, JG; OShaughnessy, M; Silverman, B; Steingart, RM; Swenson, L; Syed, K; Thadani, U; Thorsen, RD; Tonkon, MJ; Touchon, R; Uhl, G; Vaska, KJ; Wagner, SG; Weaver, CJ; Weiss, RJ; Wickemeyer, WJ; Willens, HJ; Wilson, JR; Wright, R; Yellen, L;
Indirizzi:
Univ45othenburg, Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-413 Univ Gothenburg Gothenburg Sweden SE-41345 rg Lab Cardiovasc Res, SE-413 Astra Hassle AB, Molndal, Sweden Astra Hassle AB Molndal SwedenAstra Hassle AB, Molndal, Sweden
Titolo Testata:
LANCET
fascicolo: 9169, volume: 353, anno: 1999,
pagine: 2001 - 2007
SICI:
0140-6736(19990612)353:9169<2001:EOMCXI>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; BETA-RECEPTOR BLOCKADE; MORTALITY; CARDIOMYOPATHY; MORBIDITY; DEATH; SURVIVAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Fagerberg, B Univ45othenburg, Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-413 Univ Gothenburg Gothenburg Sweden SE-41345 vasc Res, SE-413
Citazione:
A. Hjalmarson et al., "Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)", LANCET, 353(9169), 1999, pp. 2001-2007

Abstract

Background. Metoprolol can improve haemodynamics in chronic heart failure,but survival benefit has, not been proven. We investigated whether metoprolol controlled release/extended release (CR/XL) once daily, in addition to standard therapy, would lower mortality in patients with decreased ejectionfraction and symptoms of heart failure. Methods. We enrolled 3991 patients with chronic heart failure in New York Heart Association (NYHA) functional class II-IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy, in a double-blind randomised controlled study. Randomisation was preceded by a 2-week single-blind placebo run-in period. 1990 patients were randomly assigned metoprolol CR/XL 12.5 mg (NYHA III-IV) or 25.0 mg once daily (NYHA II) and 2001 were assigned placebo. The target dose was 200 mg once daily and doses were up-titrated over 8 weeks. Our primary endpoint was all-cause mortality, analysed by intention to treat. Findings. The study was stopped early on the recommendation of the independent safety committee. Mean follow-up time was 1 year. All-cause mortality was lower in the metoprolol CR/XL group than in the placebo group (145 [7.2%, per patient-year of follow-up]) vs 217 deaths [11.0%], relative risk 0.66 [95% Cl 0.53-0.81]; p = 0.00009 or adjusted for interim analyses p = 0.0062). There were fewer sudden deaths in the metoprolol CR/XL group than in the placebo group (79 vs 132, 0.59 [0.45-0.78]; p = 0.0002) and deaths from worsening heart failure (30 vs 58, 0.51 [0.33-0.79]; p = 0.0023). Interpretation. Metoprolol CR/XL once daily in addition to optimum standard therapy improved survival. The drug was well tolerated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 15:45:05